July 23rd 2025
Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly impact outcomes for patients with traditionally poor prognoses and limited options.
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
Michigan Study Finds Obesity Lowers Hospice Use Among Seniors
Dr Stuart Goldberg Discusses How COTA Analyzes Oncology Data
Dr David L. Porter Explains Variations in CAR-T Cell Trial Criteria